These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33012641)

  • 1. Extent and prevalence of post-exercise and nocturnal hypoglycemia following peri-exercise bolus insulin adjustments in individuals with type 1 diabetes.
    McCarthy O; Deere R; Churm R; Dunseath GJ; Jones C; Eckstein ML; Williams DM; Hayes J; Pitt J; Bain SC; Moser O; Bracken RM
    Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):227-236. PubMed ID: 33012641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
    Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
    Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
    Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
    Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
    Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
    Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
    Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
    Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia-prone people with Type 1 diabetes.
    Kristensen PL; Tarnow L; Bay C; Nørgaard K; Jensen T; Parving HH; Perrild H; Beck-Nielsen H; Christiansen JS; Thorsteinsson B; Pedersen-Bjergaard U
    Diabet Med; 2017 May; 34(5):625-631. PubMed ID: 28099755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial.
    Moser O; Eckstein ML; Mueller A; Birnbaumer P; Aberer F; Koehler G; Sourij C; Kojzar H; Holler P; Simi H; Pferschy P; Dietz P; Bracken RM; Hofmann P; Sourij H
    Diabetes Obes Metab; 2019 Feb; 21(2):349-356. PubMed ID: 30221457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
    Bode BW; Buse JB; Fisher M; Garg SK; Marre M; Merker L; Renard E; Russell-Jones DL; Hansen CT; Rana A; Heller SR;
    Diabet Med; 2013 Nov; 30(11):1293-7. PubMed ID: 23710902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
    Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
    Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
    Lane WS; Favaro E; Rathor N; Jang HC; Kjærsgaard MIS; Oviedo A; Rose L; Senior P; Sesti G; Soto Gonzalez A; Franek E
    Diabetes Care; 2020 Aug; 43(8):1710-1716. PubMed ID: 32209647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.
    Thalange N; Deeb L; Iotova V; Kawamura T; Klingensmith G; Philotheou A; Silverstein J; Tumini S; Ocampo Francisco AM; Kinduryte O; Danne T
    Pediatr Diabetes; 2015 May; 16(3):164-76. PubMed ID: 25683037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial.
    Battelino T; Deeb LC; Ekelund M; Kinduryte O; Klingensmith GJ; Kocova M; Kovarenko M; Shehadeh N
    Pediatr Diabetes; 2018 Nov; 19(7):1263-1270. PubMed ID: 30014589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial.
    Davies M; Sasaki T; Gross JL; Bantwal G; Ono Y; Nishida T; Tojjar D; Seino H
    Diabetes Obes Metab; 2016 Jan; 18(1):96-9. PubMed ID: 26435472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes.
    Turner D; Luzio S; Gray BJ; Bain SC; Hanley S; Richards A; Rhydderch DC; Martin R; Campbell MD; Kilduff LP; West DJ; Bracken RM
    Diabet Med; 2016 Apr; 33(4):506-10. PubMed ID: 26220149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial.
    Agesen RM; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Christiansen JS; Jensen T; Hougaard P; Parving HH; Thorsteinsson B; Tarnow L; Pedersen-Bjergaard U
    Diabetes Metab; 2016 Sep; 42(4):249-55. PubMed ID: 27068361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial.
    Dovc K; Piona C; Yeşiltepe Mutlu G; Bratina N; Jenko Bizjan B; Lepej D; Nimri R; Atlas E; Muller I; Kordonouri O; Biester T; Danne T; Phillip M; Battelino T
    Diabetes Care; 2020 Jan; 43(1):29-36. PubMed ID: 31575640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.